- Home
- SYRE vs EAT Comparison
SYRE vs EAT Comparison
Compare SYRE & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | EAT |
|---|---|---|
| Founded | 2013 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.1B |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | SYRE | EAT |
|---|---|---|
| Price | $96.64 | $210.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 23 |
| Target Price | $122.53 | ★ $264.73 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.65 |
| EPS | N/A | ★ 2.64 |
| Revenue | N/A | ★ $5,807,400,000.00 |
| Revenue This Year | N/A | $8.54 |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | ★ N/A | $83.50 |
| Revenue Growth | N/A | ★ 7.86 |
| 52 Week Low | $21.15 | $101.37 |
| 52 Week High | $110.18 | $254.99 |
Technical Indicators
Market Signals| Indicator | SYRE | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 60.41 |
| Support Level | $93.45 | $186.08 |
| Resistance Level | $105.09 | $231.74 |
| Average True Range (ATR) | 4.29 | 11.08 |
| MACD | 1.22 | 2.98 |
| Stochastic Oscillator | 93.81 | 77.15 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About EAT Brinker International Inc.
Brinker International is a leading casual dining operator and franchisor. Chili's, its largest banner and the second-largest casual dining concept in the US, is known for its American/Southwest-inspired menu. In fiscal 2026, the segment generated $5.3 billion in revenue (92% of consolidated sales) across 1,114 company-owned restaurants in the US and 469 franchised locations (the bulk of which are in international markets). The Italian casual-dining concept Maggiano's accounts for the remainder of the business, with 52 domestic units.